FLT3 and acute myeloid leukemia: Furthermore, the prominent effect of cladribine included in treatment protocols for AML, especially in patients with unfavorable cytogenetics and FLT3-ITD mutations, has been proven in previous PALG studies (18–20), which enhanced the advantage of CLAG-M.